Apogee Therapeutics Inc
APGE37.870USD
+0.930+2.52%
Close 08/26, 16:00（ET）Quotes delayed by 15 min
2.22BMarket Cap
LossP/E TTM
More Details of Apogee Therapeutics Inc Company
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Company Info
Ticker SymbolAPGE
Company nameApogee Therapeutics Inc
IPO dateJul 14, 2023
CEODr. Michael Henderson, M.D.
Number of employees196
Security typeOrdinary Share
Fiscal year-endJul 14
Address221 Crescent St.
CityWALTHAM
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02453
Phone16503945230
Websitehttps://apogeetherapeutics.com/
Ticker SymbolAPGE
IPO dateJul 14, 2023
CEODr. Michael Henderson, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Carl Dambkowski, M.D.
Mr. Carl Dambkowski, M.D.
Chief Medical Officer
Chief Medical Officer
131.73K
-2.03%
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Director
Independent Director
51.17K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Chairman of the Board
Independent Chairman of the Board
20.00K
--
Mr. Nimish Shah
Mr. Nimish Shah
Independent Director
Independent Director
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Mr. William (Bj) Jones, Jr.
Mr. William (Bj) Jones, Jr.
Independent Director
Independent Director
--
--
Ms. Jennifer Fox
Ms. Jennifer Fox
Independent Director
Independent Director
--
--
Dr. Michael Henderson, M.D.
Dr. Michael Henderson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Andrew Gottesdiener, M.D.
Dr. Andrew Gottesdiener, M.D.
Independent Director
Independent Director
--
--
Ms. Jane Pritchett Henderson
Ms. Jane Pritchett Henderson
Chief Financial Officer
Chief Financial Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Carl Dambkowski, M.D.
Mr. Carl Dambkowski, M.D.
Chief Medical Officer
Chief Medical Officer
131.73K
-2.03%
Mr. Tomas Kiselak
Mr. Tomas Kiselak
Independent Director
Independent Director
51.17K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Chairman of the Board
Independent Chairman of the Board
20.00K
--
Mr. Nimish Shah
Mr. Nimish Shah
Independent Director
Independent Director
--
--
Mr. Peter Harwin
Mr. Peter Harwin
Independent Director
Independent Director
--
--
Mr. William (Bj) Jones, Jr.
Mr. William (Bj) Jones, Jr.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
VR Adviser, LLC
18.42%
Fidelity Management & Research Company LLC
14.39%
Wellington Management Company, LLP
10.59%
RTW Investments L.P.
5.88%
Driehaus Capital Management, LLC
5.01%
Other
45.70%
Shareholders
Shareholders
Proportion
VR Adviser, LLC
18.42%
Fidelity Management & Research Company LLC
14.39%
Wellington Management Company, LLP
10.59%
RTW Investments L.P.
5.88%
Driehaus Capital Management, LLC
5.01%
Other
45.70%
Shareholder Types
Shareholders
Proportion
Investment Advisor
39.28%
Investment Advisor/Hedge Fund
38.80%
Hedge Fund
25.70%
Venture Capital
19.59%
Corporation
4.75%
Research Firm
4.74%
Individual Investor
2.85%
Private Equity
2.56%
Bank and Trust
0.30%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
361
64.81M
140.75%
-3.82M
2025Q1
358
68.35M
148.52%
-1.29M
2024Q4
327
64.90M
141.09%
-712.20K
2024Q3
294
62.28M
112.13%
-1.08M
2024Q2
266
60.08M
139.61%
+8.71M
2024Q1
229
52.05M
122.88%
+15.40M
2023Q4
155
40.73M
116.78%
+8.63M
2023Q3
114
37.13M
101.02%
+18.30M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
VR Adviser, LLC
8.49M
18.44%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
7.02M
15.24%
-5.76K
-0.08%
Mar 31, 2025
Wellington Management Company, LLP
5.49M
11.91%
+968.39K
+21.44%
Mar 31, 2025
RTW Investments L.P.
2.71M
5.89%
--
--
Mar 31, 2025
Driehaus Capital Management, LLC
2.34M
5.08%
-265.75K
-10.20%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.64M
5.73%
-120.52K
-4.37%
Mar 31, 2025
Access Industries, Inc.
2.19M
4.76%
+250.00K
+12.88%
Sep 30, 2024
The Vanguard Group, Inc.
2.08M
4.51%
-14.99K
-0.72%
Mar 31, 2025
Fairmount Funds Management LLC
2.05M
4.45%
--
--
Mar 31, 2025
Braidwell LP
1.54M
3.35%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Wed, Aug 6
Updated: Wed, Aug 6
Name
Proportion
ALPS Medical Breakthroughs ETF
1.35%
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
Goldman Sachs Future Health Care Equity ETF
0.87%
First Trust Multi-Manager Small Cap Opportunities ETF
0.46%
SPDR S&P Biotech ETF
0.41%
Direxion Daily S&P Biotech Bull 3X Shares
0.26%
ProShares Ultra Nasdaq Biotechnology
0.22%
Invesco Nasdaq Biotechnology ETF
0.17%
iShares Biotechnology ETF
0.15%
Optimize Strategy Index ETF
0.14%
View more
ALPS Medical Breakthroughs ETF
Proportion1.35%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.93%
Goldman Sachs Future Health Care Equity ETF
Proportion0.87%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.46%
SPDR S&P Biotech ETF
Proportion0.41%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.26%
ProShares Ultra Nasdaq Biotechnology
Proportion0.22%
Invesco Nasdaq Biotechnology ETF
Proportion0.17%
iShares Biotechnology ETF
Proportion0.15%
Optimize Strategy Index ETF
Proportion0.14%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
